HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kempf, K. E. Articles by Rubin, A. S. Search for Related Content PubMed Articles by Kempf, K. E. Articles by Rubin, A. S.

Transient Suppression of the Humoral Immune Response Mediated by a Factor Derived from Specifically Activated, Doubly Primed Lymphoid Cells¹

From the University of Texas at Austin, Department of Microbiology, Austin, Texas 78712

Abstract

In cultures of sheep erythrocyte- (SRBC) stimulated spleen cells from mice immunized with tetanus toxoid (TT) and horse erythrocytes (HRBC) 30 to 90 days earlier, the addition of both HRBC (day 0) and TT (day 2) resulted in significant suppression of the anti-SRBC plaque-forming cell (PFC) response compared to the response of similar cultures maintained without the priming antigens. The observed inhibition was due to the presence of a soluble factor that was released into the supernatant fluid of the specifically stimulated, primed population of lymphoid cells between 72 and 120 hr after culture initiation. The active mediator, a macromolecule of 24,000 daltons as determined by gel filtration over Sephadex G-150 and Ultrogel AcA 44, was suppressive when added within 24 hr, but not 48 hr, of assay for PFC against the reference SRBC antigen. The transiently acting soluble suppressor (TASS) was not overtly cytotoxic since total cell recovery and viability were unaffected in its presence. The results presented here are discussed in relation to a possible mechanism of action in which the negative regulation of immunoglobulin production is favored once a minimum level of immune reactivity is reached.

Footnotes

¹ This work was supported in part by National Institutes of Health Grant AI-12752.